About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Drug Repurposing Market Size, Industry Trends And Future Outlook By 2033
Drug Repurposing Market

Drug Repurposing Market Size, Share & Trends Analysis Report By Method (Drug Centric, Disease Centric, Target Centric), By Application (Oncology, Autoimmune Diseases, Rare Diseases, Others), By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic and Research Institutions) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRPH57084DR
Last Updated : March 27, 2025
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Drug Repurposing Market Introduction
    2. By Method
      1. Introduction
        1. Method By Value
      2. Drug Centric
        1. By Value
      3. Disease Centric
        1. By Value
      4. Target Centric
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Rare Diseases
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Academic and Research Institutions
        1. By Value
    1. Introduction
    2. By Method
      1. Introduction
        1. Method By Value
      2. Drug Centric
        1. By Value
      3. Disease Centric
        1. By Value
      4. Target Centric
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Rare Diseases
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Academic and Research Institutions
        1. By Value
    5. U.S.
      1. By Method
        1. Introduction
          1. Method By Value
        2. Drug Centric
          1. By Value
        3. Disease Centric
          1. By Value
        4. Target Centric
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Rare Diseases
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Academic and Research Institutions
          1. By Value
    6. Canada
    1. Introduction
    2. By Method
      1. Introduction
        1. Method By Value
      2. Drug Centric
        1. By Value
      3. Disease Centric
        1. By Value
      4. Target Centric
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Rare Diseases
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Academic and Research Institutions
        1. By Value
    5. U.K.
      1. By Method
        1. Introduction
          1. Method By Value
        2. Drug Centric
          1. By Value
        3. Disease Centric
          1. By Value
        4. Target Centric
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Rare Diseases
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Academic and Research Institutions
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Method
      1. Introduction
        1. Method By Value
      2. Drug Centric
        1. By Value
      3. Disease Centric
        1. By Value
      4. Target Centric
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Rare Diseases
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Academic and Research Institutions
        1. By Value
    5. China
      1. By Method
        1. Introduction
          1. Method By Value
        2. Drug Centric
          1. By Value
        3. Disease Centric
          1. By Value
        4. Target Centric
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Rare Diseases
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Academic and Research Institutions
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Method
      1. Introduction
        1. Method By Value
      2. Drug Centric
        1. By Value
      3. Disease Centric
        1. By Value
      4. Target Centric
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Rare Diseases
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Academic and Research Institutions
        1. By Value
    5. UAE
      1. By Method
        1. Introduction
          1. Method By Value
        2. Drug Centric
          1. By Value
        3. Disease Centric
          1. By Value
        4. Target Centric
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Rare Diseases
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Academic and Research Institutions
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Method
      1. Introduction
        1. Method By Value
      2. Drug Centric
        1. By Value
      3. Disease Centric
        1. By Value
      4. Target Centric
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Rare Diseases
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Academic and Research Institutions
        1. By Value
    5. Brazil
      1. By Method
        1. Introduction
          1. Method By Value
        2. Drug Centric
          1. By Value
        3. Disease Centric
          1. By Value
        4. Target Centric
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Rare Diseases
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Academic and Research Institutions
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Drug Repurposing Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. BioXcel Therapeutics Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Rejuvenate Biomed NV.
    3. SOM Biotech, S.L.
    4. Biogen Inc
    5. Bristol-Myers Squibb Company
    6. Every Cure
    7. NovaLead Pharma Pvt. Ltd.
    8. AstraZeneca PLC
    9. Hoffmann-La Roche AG
    10. Pfizer Inc.
    11. Johnson & Johnson Services, Inc.
    12. LifeArc
    13. Takeda Pharmaceutical Company Limited
    14. Sanofi S.A.
    15. GSK plc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Bispecific Antibodies Market Size The global bispecific antibodies market size was valued at USD 11.84 billion in 2024 and is expected to grow from USD 17.10 billion in 2025 to USD 323.21 billion by 2033, growing at a CAGR of 44.4% du
Buy Now
Global Report
The global X-Ray Inspection System Market size was valued at USD 734.5 Million in 2022 and is projected to reach USD 1231.3 Million by 2031, registering a CAGR of 6.6% during the forecast period (2023-2031). The rising awareness of the bene
Buy Now
Global Report
Inflight Catering Market Size and Trends The global inflight catering market size was valued at USD 13.62 billion in 2023. It is projected to reach from USD 15.16 billion in 2024 to USD 35.75 billion by 2032, growing at a CAGR of 11.32% during the f
Buy Now
Global Report
Bladder Scanners Market Size The global bladder scanners market size was valued at USD 149.28 million in 2024 and is projected to grow from USD 162.36 million in 2025 to reach USD 270.46 million by 2033, exhibiting a CA
Buy Now
Global Report
Hair Removal Wax Market Size The global hair removal wax market size was valued at USD 14426.26 million in 2024 and is projected to reach from USD 15133.14 million in 2025 to USD 22188.76 million by 2033, growing at a CAGR of 4.9% during t
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.